IL2RB and neoplasm: The complete tumor responses of both the primary and contralateral tumors were observed in 60% of the Ad-p53 + CD122/132 + anti-PD-1 treatment group (six of ten animals) and there were no complete tumor responses in any of the 70 animals in the other treatment groups (p value <0.0001 by two-sided Fisher’s Exact test comparing Ad-p53 + CD122/132 + anti-PD-1 treatment group vs. animals in all other treatment groups; p value <0.011 by two-sided Fisher’s Exact test comparing Ad-p53 + CD122/132 + anti-PD-1 treatment group vs. any other treatment group).